{"id":383248,"date":"2025-06-18T00:00:00","date_gmt":"2025-06-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0013-2025-biopharma-gout-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:25:57","modified_gmt":"2026-03-31T10:25:57","slug":"dlsfmd0013-2026-biopharma-gout-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0013-2026-biopharma-gout-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Gout &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Gout, a type of inflammatory arthritis, results from the persistent elevation of serum uric acid (<abbr title=\"serum uric acid\">sUA<\/abbr>) levels. The condition is characterized by sudden and severe flares that cause significant discomfort. Chronic gout is primarily managed with urate-lowering therapies (<abbr title=\"urate-lowering therapy\">ULT<\/abbr>s), including xanthine oxidase inhibitors (<abbr title=\"xanthine oxidase inhibitor\">XOI<\/abbr>s), uricosuric agents, and uricase analogues. Acute gout flares are treated with nonsteroidal anti-inflammatory drugs (<abbr title=\"nonsteroidal anti-inflammatory drug\">NSAID<\/abbr>s), colchicine, corticosteroids, and anti-<abbr title=\"interleukin\">IL<\/abbr>-1 agents, which also serve as prophylactic measures while initiating <abbr data-abbreviation-entity=\"10524\" title=\"urate-lowering therapy\">ULT<\/abbr>s to prevent flares. Despite existing treatments, there remains considerable need for safer, less frequently dosed agents for chronic refractory gout. We expect the gout therapy market to expand over the 2024-2034 forecast period, driven by the increasing number of diagnosed cases and the introduction of novel drugs such as Sobi Therapeutics\u2019 NASP (SEL-212), Atom Therapeutics\u2019 lingdolinurad (ABP-671), Arthrosi Therapeutics\u2019 pozdeutinurad (AR882), and Olatec Therapeutics\u2019 dapansutrile.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the incidence and prevalence of gout in the major pharmaceutical markets under study?<\/li>\n<li>How is gout currently treated? What are experts\u2019 opinions of Amgen\u2019s Krystexxa (pegloticase) as a treatment for chronic refractory gout?<\/li>\n<li>What is the commercial potential of emerging therapies? How do leaders in the field of gout management rate these drug candidates?<\/li>\n<li>How will the gout therapy market evolve over the next 10 years?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/li>\n<li><strong>Primary research: <\/strong>Country-specific interviews with thought-leading rheumatologists. Supported by survey data collected for this and other Clarivate research.<\/li>\n<li><strong>Epidemiology: <\/strong>Incidence and prevalence of diagnosed gout population by country and drug-treated rates.<\/li>\n<li><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies.<\/li>\n<li><strong>Market forecast features: <\/strong>10-year, annualized, drug-level sales and patient share of key gout therapies through 2034, segmented by brands \/ generics.<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p style=\"\">Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW229817085 BCX0 round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-383248","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gout","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/383248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/383248\/revisions"}],"predecessor-version":[{"id":575772,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/383248\/revisions\/575772"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=383248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}